Nobel laureate Sir Michael Houghton and colleagues at Applied Pharmaceutical Innovation (API) outline how rigorous early ...
By Sahil Pandey and Puyaan Singh April 14 (Reuters) - Amazon's cloud unit on Tuesday launched Amazon Bio Discovery, an ...
Key market opportunities for bispecific antibody drug conjugates (BsADCs) include their potential to revolutionize cancer treatment by targeting dual antigens, addressing tumor heterogeneity. With ...
WASHINGTON — Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a dual hub centered in the United States and China, according to ...
In this Q&A, Jenna DiRito, PhD, COO and co-founder of Revalia Bio, discusses how earlier, human-relevant data is reshaping go ...
The Blood-Brain Barrier (BBB) is a highly selective interface that protects the brain by regulating the entry of nutrients, signaling molecules, and ...
In modern drug discovery, successfully navigating the progress from molecular concept to viable therapeutic often hinges on ...
Moving a potential therapy from the laboratory to the pharmacy has always been a slow, incremental journey. “Drug development is a multi-stage process,” says Nichola McCann, associate principal ...
CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the ...
The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward human-biology-based testing methods for monoclonal antibody programs. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results